Compare COCO & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | NUVB |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2021 | N/A |
| Metric | COCO | NUVB |
|---|---|---|
| Price | $53.69 | $8.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $55.13 | $10.63 |
| AVG Volume (30 Days) | 623.0K | ★ 6.1M |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.16 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $609,286,000.00 | $26,748,000.00 |
| Revenue This Year | $18.22 | $609.55 |
| Revenue Next Year | $13.69 | $197.91 |
| P/E Ratio | $46.37 | ★ N/A |
| Revenue Growth | 23.12 | ★ 1137.19 |
| 52 Week Low | $25.79 | $1.54 |
| 52 Week High | $55.29 | $9.75 |
| Indicator | COCO | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 61.16 |
| Support Level | $52.87 | $9.06 |
| Resistance Level | $54.89 | $9.75 |
| Average True Range (ATR) | 1.33 | 0.44 |
| MACD | -0.36 | -0.09 |
| Stochastic Oscillator | 61.66 | 58.21 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.